New Vaccine Shows Promise Against Typhoid and Invasive Salmonella in First Human Trial
.png){kind=logo}
Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) have completed a successful Phase 1 clinical trial of a novel vaccine designed to protect against both typhoid fever and invasive non-typhoidal Salmonella--two major causes of illness and death among children in sub-Saharan Africa. Results were recently published in the journal Nature Medicine.
“In 2017, sub-Saharan Africa saw over 420,000 cases of Salmonella disease and 66,000 deaths, primarily among children,” said Mark T. Gladwin, MD, Dean of the UM School of Medicine. “Typhoid fever caused an additional 650,000 cases and nearly 9,000 deaths in the region. A single vaccine that protects against both could be a game-changer for global pediatric health.”